menu ☰
menu ˟

FDA panel advises easing restrictions on rosiglitazone

10 Jun 2013

A joint Food and Drug Administration advisory panel has voted to ease the current stringent restriction on prescription of the antidiabetes drug rosiglitazone (marketed by GlaxoSmithKline as Avandia), despite lingering concerns about its cardiovascular safety.

Date: 
10 June 2013

Click here to view the full article which appeared in